Here is the latest news from Theralase. Reading through through the news real meat and bones is the following.

• “Theralase and UHN will work together to evaluate Theralase’s patented and patent pending platform of novel Ruthenium (“Ru”) and Osmium (“Os”) based PDCs for new cancer indications, including: lung, melanoma and brain cancer. ” – This testing on different forms of cancer will obviously take some time. If there are any positive results it could be a new section of the cancer division.

Click here to read of the full release and let us know what you think.